Prognostic value of Helix pomatia in breast cancer. International (Ludwig) Breast Cancer Study Group
- PMID: 8318406
- PMCID: PMC1968298
- DOI: 10.1038/bjc.1993.303
Prognostic value of Helix pomatia in breast cancer. International (Ludwig) Breast Cancer Study Group
Abstract
Six hundred and eighty-four primary breast cancers from the International (Ludwig) Breast Cancer Study Group (IBCSG) were studied for Helix pomatia lectin (HPA) binding. There was a weak correlation between lymph node-positive and HPA positive (P = 0.04). In our series there was a large advantage in disease-free survival (DFS) and overall survival (OS) for node-negative patients (P < 0.0001 DFS and OS). However, there was no such advantage for HPA-negative patients (P = 0.23 DFS and P = 0.32 OS). We conclude that in this randomised patient group HPA is of no clinical predictive value.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical